Great Novel Therapeutics Biotech & Medicals Profit Margin

The latest profit margin for 7427.TWO is -2496.14% as of June 2026. That compares with -3002.47% in the prior-year period — up 16.9% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Great Novel Therapeutics Biotech & Medicals's historical trend and sector peers before judging valuation or financial health.

Over the past year, 7427.TWO's profit margin moved from -3002.47% to -2496.14% — a 16.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Great Novel Therapeutics Biotech & Medicals's valuation or profitability profile.

Against Healthcare companies, 7427.TWO currently prints -2496.14% for profit margin, while the sector average sits near 10.58%. That is roughly 23692.0% below the sector mean. Large gaps often invite a closer look at Great Novel Therapeutics Biotech & Medicals's growth, margins, and balance sheet.

Profit Margin shows how effectively Great Novel Therapeutics Biotech & Medicals converts resources into returns. At -2496.14%, 7427.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3002.47% in the prior-year period — up 16.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 7427.TWO's profit margin (-2496.14%), review year-over-year change from -3002.47%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.